Key result
Venous blood line bolus of enoxaparin increased median post-dialysis anti-factor Xa activity compared to arterial administration.
Why the study?
Although venous blood line injection is recommended to prevent initial LMWH loss through dialyzers, LMWH is still frequently injected into the arterial line.
Does enoxaparin administered through the venous blood line improve antifactor Xa activity and prevent clotting compared to arterial blood line administration in hemodialysis patients?
Does enoxaparin administered through the venous blood line improve antifactor Xa activity and prevent clotting compared to arterial blood line administration in hemodialysis patients?
Venous blood line administration of enoxaparin during hemodialysis increases post-dialysis aXa activity compared to arterial administration, which may increase bleeding risk in certain dialysis modalities.
Answers are grounded in this paper and cite their sources.
Venous enoxaparin may increase aXa activity and overdosing risk in HF-HD/MCO-HD; leaves open route- and modality-specific dosing guidance.
Low-molecular weight heparins (LMWH) are widely used for preventing clotting during hemodialysis (HD). Although injection in the venous blood line is recommended to avoid initial loss of LMWH through the dialyzer, LMWH is still frequently administered in the arterial blood line at the start of dialysis. This study aimed to compare the safety and efficacy of the same enoxaparin dose administered through the venous blood line or arterial blood line. We also evaluated antifactor Xa (aXa) activity according to the injection route and dialysis modalities: high-flux (HF) HD, medium cut-off (MCO) HD, and online hemodiafiltration (OL-HDF). Forty-three patients were studied over 18 consecutive dialysis sessions using a fixed enoxaparin dose (20 or 40 mg), first administered through the arterial blood line bolus and then through the venous blood line for another 18 sessions. Compared to arterial blood line administration, venous blood line bolus resulted in a significant increase in median post-dialysis aXa activity: 0.16 (0.1-0.6) IU/ml versus 0.31 (0.1-1.3) IU/ml, respectively, p = 0.006. After arterial blood line bolus of 40 mg enoxaparin, median post-dialysis aXa activity was significantly lower with OL-HDF compared to HF-HD: 0.14 (0.1-0.35) versus 0.32 (0.15-0.49), p = 0.02. A trend for lower clotting within lines and bubble trap using venous blood line bolus was observed. In conclusion, venous blood line enoxaparin injection is safe in OL-HDF patients. However, in HF-HD and MCO-HD, venous blood line injection of 40 mg enoxaparin may increase overdosing risk. Thus, aXa activity should be monitored in HF-HD and MCO-HD patients at risk of bleeding and/or on vitamin K antagonists and careful surveillance is required when administering a 40 mg enoxaparin dose through the venous blood line route.
No takes yet. Share an insight, caveat, or question.
Belmouaz et al. (2022) studied Hemodialysis (n=43). Enoxaparin injection in the venous blood line vs. Enoxaparin injection in the arterial blood line was evaluated on median post-dialysis antifactor Xa (aXa) activity (IU/ml) (p=0.006). Venous blood line bolus of enoxaparin increased median post-dialysis anti-factor Xa activity compared to arterial administration.
Synapse has enriched 10 related papers. Consider them for comparative context: